Researchers isolated a molecule that may be under-produced in the guts of patients
Researchers at the Weizmann Institute of Science have shown in mice that intestinal microbes, collectively termed the gut microbiome, may affect the course of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. As reported today in Nature,progression of an ALS-like disease was slowed after the mice received certain strains of gut microbes or substances known to be secreted by these microbes. Preliminary results suggest that the findings on the regulatory function of the microbiome may be applicable to human patients with ALS.
“Our long-standing scientific and medical goal is to elucidate the impact of the microbiome on human health and disease, with the brain being a fascinating new frontier,” says Prof. Eran Elinav of the Immunology Department. His team performed the study together with that of Prof. Eran Segal of the Computer Science and Applied Mathematics Department. Segal elaborates: “Given increasing evidence that microbiome affects brain function and disease, we wanted to study its potential role in ALS.” The study was led by postdoctoral fellows Drs. Eran Blacher and Stavros Bashiardes, and by staff scientist Dr. Hagit Shapiro, all in the Elinav lab. They collaborated with Dr. Daphna Rothschild, a postdoctoral fellow in Eran Segal’s lab, and Dr. Marc Gotkine, Head of the Motor Neuron Disease Clinic at Hadassah Medical Center, as well as with other scientists from Weizmann and elsewhere.
The scientists started out demonstrating in a series of experiments that the symptoms of an ALS-like disease in transgenic mice worsened after these mice were given broad-spectrum antibiotics to wipe out a substantial portion of their microbiome. In addition, the scientists found that growing these ALS-prone mice in germ-free conditions (in which, by definition, mice carry no microbiome of their own), is exceedingly difficult, as these mice had a hard time surviving in the sterile environment. Together, these results hinted at a potential link between alterations in the microbiome and accelerated disease progression in mice that were genetically susceptible to ALS.
Next, using advanced computational methods, the scientists characterized the composition and function of the microbiome in the ALS-prone mice, comparing them to regular mice. They identified 11 microbial strains that became altered in ALS-prone mice as the disease progressed or even before the mice developed overt ALS symptoms. When the scientists isolated these microbial strains and gave them one by one – in the form of probiotic-like supplements – to ALS-prone mice following antibiotic treatment, some of these strains had a clear negative impact on the ALS-like disease. But one strain, Akkermansia muciniphila, significantly slowed disease progression in the mice and prolonged their survival.
To reveal the mechanism by which Akkermansia may be producing its effect, the scientists examined thousands of small molecules secreted by the gut microbes. They zeroed in on one molecule called nicotinamide (NAM): Its levels in the blood and in the cerebrospinal fluid of ALS-prone mice were reduced following antibiotic treatment and increased after these mice were supplemented with Akkermansia, which was able to secrete this molecule. To confirm that NAM was indeed a microbiome-secreted molecule that could hinder the course of ALS, the scientists continuously infused the ALS-prone mice with NAM. The clinical condition of these mice improved significantly. A detailed study of gene expression in their brains suggested that NAM improved the functioning of their motor neurons.
One strain significantly slowed disease progression in the mice and prolonged their survival
Finally, the researchers examined the microbiome and metabolite profiles of 37 human ALS patients and compared them to those of family members sharing the same household. A detailed genomic analysis suggested that the gut microbiomes of ALS patients were distinct in composition and functional features from those of healthy controls. In particular, numerous microbial genes involved in the synthesis of NAM were significantly suppressed in ALS patients. An analysis of thousands of small molecules in the blood also revealed a distinct pattern in ALS patients as compared to controls. Here too, many of the intermediary molecules involved in the NAM synthesis were altered in the blood of ALS patients. When the researchers tested the levels of NAM itself, they found these to be significantly reduced in both the blood and the brain of 60 human ALS patients as compared to controls. Moreover, there was a correlation between reduced NAM levels and the degree of muscle weakness in the patients.
“These findings are only a first step towards achieving a comprehensive understanding of the potential impact of the microbiome on ALS,” Elinav says, “but they suggest that in the future, various means of altering the microbiome may be harnessed for developing new therapeutic options for ALS.”
Learn more: Gut Microbes May Affect the Course of ALS
The Latest on: Amyotrophic lateral sclerosis
[google_news title=”” keyword=”amyotrophic lateral sclerosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Amyotrophic lateral sclerosis
- Japan Tobacco describes NLRP3 inflammasome inhibitorson March 30, 2023 at 8:50 am
gout, inflammatory bowel disease, amyotrophic lateral sclerosis, multiple sclerosis, nonalcoholic steatohepatitis (NASH), Alzheimer’s and Parkinson’s diseases.
- Amyotrophic Lateral Sclerosis Treatment Market Size to Hit USD 436.17 Million by 2027 at 5.52% CAGR Reported by Brandessence Market Researchon March 30, 2023 at 7:20 am
The Global Amyotrophic Lateral Sclerosis Treatment Market was worth USD 316.01 million in 2020 and is poised to amass a valuation of USD 436.17 million by 2027, witnessing a CAGR of 5.52% over the ...
- Capitalizing on Amyotrophic Lateral Sclerosis (ALS) Treatment Trends: Maximizing Profits from 2023-2119on March 29, 2023 at 9:22 pm
The “Amyotrophic Lateral Sclerosis (ALS) Treatment Market” offers an all-inclusive view of the market, including a comprehensive overview of the products, scope, and segments based on types, ...
- Amyotrophic Lateral Sclerosis Treatment Market Outlook By 2031on March 29, 2023 at 9:15 pm
The MarketWatch News Department was not involved in the creation of this content. Mar 30, 2023 (The Expresswire) -- The "Amyotrophic Lateral Sclerosis Treatment Market" Study Describes how the ...
- Spiritwood Lake woman with ALS spreading awareness about diseaseon March 29, 2023 at 8:55 pm
A 61-year-old Spiritwood Lake woman wants others to be aware of amyotrophic lateral sclerosis so more research can be conducted to eventually find a cure for the disease. Sue Backer was officially ...
- Seelos Therapeutics Announces Business Update on its Key Programson March 29, 2023 at 3:04 pm
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today ...
- News - Amyotrophic lateral sclerosison March 28, 2023 at 11:29 am
Clene Nanomedicine, a part of Clene Inc, has reported significantly improved survival in amyotrophic lateral sclerosis (ALS) patients initially treated with CNM-Au8 compared to initially randomized ...
- There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Studyon March 28, 2023 at 5:03 am
Coya Therapeutics (NASDAQ: COYA) has just reported proof of concept data from its trial for COYA 302, a new combination drug for treating amyotrophic lateral sclerosis (ALS).
- What Are the Earliest Signs of Amyotrophic Lateral Sclerosis (ALS)?on March 21, 2023 at 2:23 pm
Amyotrophic lateral sclerosis (ALS) is a rare progressive disease affecting about 31,000 people in the United States. Known also as Lou Gehrig’s disease, it affects the nerve cells that control ...
- Amyotrophic Lateral Sclerosis Market is expected to reach US$ 1332.22 Million by 2033 at a CAGR of 6%on March 19, 2023 at 8:32 pm
The global Amyotrophic Lateral Sclerosis Market is estimated to generate a market value of US$ 743.90 Million in 2023 and a market value of US$ 1332.22 Million by achieving a CAGR of 6% between 2023 ...
via Bing News